Read This First
This page is not built on clinical evidence. It is built on the FDA's compounding record, the anti-doping laboratories' analyses of seized product, and peptide chemistry. What ipamorelin does in people is covered on the library entry; this page is about what is in the vial.
Ipamorelin is one of the few peptides that has been found, in black-market vials analysed by anti-doping laboratories, to be a different molecule from the one on the label: the same sequence with an extra glycine on the front.12 That finding, twice replicated, is the fact this page is organised around.
Legal Status
Where Does Ipamorelin Stand?
Approved nowhere. Novo Nordisk did not develop it past early studies, Helsinn's programme for postoperative ileus ended after negative Phase 2 results, and no regulator has approved any product containing it.
In the United States it occupies a specific and slightly unusual position. In September 2023 the FDA placed ipamorelin acetate in Category 2 of its interim compounding policy, the category for substances that may present significant safety risks, under both the 503A pharmacy policy and the 503B outsourcing facility policy. As of April 2026 the 503A nomination is listed as withdrawn, but the substance remains in active Category 2 under 503B, one of only a handful of peptides still there alongside GHRP-2 and GHRP-6.3
What Does the FDA Say About It?
The entry, in full: compounded drugs containing ipamorelin acetate "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities. Ipamorelin acetate also contains unnatural amino acids, which add to the complexity of peptide characterization. A study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility. FDA has not identified safety-related information regarding ipamorelin acetate via certain other injectable routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans via those routes."3
"Certain other injectable routes" means subcutaneous, the only route used outside a hospital. The regulator is saying that for the way everyone uses this compound, it has nothing.
Can It Be Compounded?
Not lawfully in the United States. Ipamorelin is not a component of an approved drug, has no USP monograph, is not on the 503A bulks list, and has not been before the Pharmacy Compounding Advisory Committee at all. Its stack partner CJC-1295 has, and was rejected unanimously in December 2024.4 Neither half of "CJC/Ipa" has a lawful compounding route.
Product Identity
What Makes This Peptide Hard to Verify?
Three of its five residues are not ordinary amino acids: aminoisobutyric acid, D-2-naphthylalanine and D-phenylalanine.5 The FDA's phrase for the consequence is that unnatural amino acids "add to the complexity of peptide characterization."3 In practice: the D-residues can be substituted with their L-forms by a careless synthesis, producing a molecule of identical mass and different activity; and standard amino acid analysis does not cover the unnatural ones, so a laboratory has to know what it is looking for.
What Has Been Found in Seized Product?
Two independent analyses, and they agree.
In 2018 an anti-doping laboratory analysing black-market growth-promoting products identified three GHRP analogues that were the labelled peptide extended by a glycine at the N-terminus: Gly-GHRP-6, Gly-GHRP-2 and Gly-ipamorelin. The identity of Gly-ipamorelin was confirmed by custom synthesis.1 In 2019 Danish customs seizures showed the same pattern for GHRP-2, GHRP-6, ipamorelin and modified GRF 1-29: in all cases, an extra glycine.2
Neither paper says why. A glycine extension could be a synthesis artefact, a cheaper protected intermediate sold as finished product, or a deliberate change to evade a test that targets the exact mass of ipamorelin. Whatever the cause, the consequence for a buyer is the same: a purity certificate on such a vial would show a clean single peak, because the product is pure. It is a pure molecule that has never been studied in anything.
Purity Testing Versus Identity Testing
| Test | Question it answers | Question it cannot answer |
|---|---|---|
| HPLC purity | What proportion of the sample is one substance | Whether that substance is ipamorelin, Gly-ipamorelin, or an L-for-D epimer |
| Mass spectrometry identity | Whether the mass matches | Epimers have the same mass; a glycine extension differs by 57 daltons and only shows if someone looks |
| Endotoxin assay | Whether bacterial cell-wall fragments are present | Identity or content |
| Chiral analysis | Whether the D-residues are D | Rarely offered; almost never on a retail certificate |
For this compound a mass spectrometry result that reports the observed mass, not just "conforms," is worth asking for. It is the one number on a certificate that would have caught what the anti-doping laboratories found.
Certificates of Analysis
What a Certificate Is
A laboratory report on one batch. Read it for the laboratory's name and independence from the seller, the lot number and whether it matches the vial, the date, the exact substance named including salt form, and which tests were actually run rather than mentioned.
What It Cannot Establish
That the vial in hand came from the batch tested. Its value rests on a chain of custody the buyer cannot inspect. A certificate is a PDF; nothing about the format prevents reuse or fabrication, and the FDA has documented fabricated labels and fictitious pharmacies on gray-market peptide products.6
Blends
Ipamorelin is commonly sold pre-mixed with CJC-1295 in a fixed ratio. A certificate for a blend has to report each component's identity and quantity separately to mean anything, and a single purity figure for a two-peptide mixture is not a meaningful number. Ask what it refers to.
"Research Use Only"
Does the Label Change Anything?
No. It is a liability position adopted by the seller, not a regulatory category. The FDA has held in warning letters to peptide sellers that the disclaimer does not survive product copy establishing human use.7 A page describing growth hormone pulses, muscle, fat loss and a bedtime injection, followed by a line that the vial is not for human consumption, has supplied the agency's argument.
Storage and Handling
What Is Known
No manufacturer-validated storage specification exists for any product a consumer can buy. Ipamorelin is a short, amidated peptide with unnatural residues chosen partly for enzymatic stability, and as peptides go it is likely robust as a dry powder. Nothing about that has been measured on a retail product, and reconstituted solutions follow the ordinary rules: refrigerate, avoid heat, avoid repeated freeze-thaw, and expect gradual loss over weeks.
Multi-Dose Vials
Community protocols inject ipamorelin two or three times a day.8 That is many entries into one rubber stopper. The FDA's guidance for compounded injectables is to discard a multi-dose vial within 28 days of first use regardless of what remains or what the supplier says, and to use a new sterile needle and syringe for every dose.6 With three entries a day, the contamination question is not theoretical.
Signs to Stop Rather Than Proceed
Injection-site redness, swelling or hardness that grows with successive doses
Marked increase in hunger, which is what a ghrelin mimetic does and what the mouse data predict, and which a user should recognise as the compound rather than as themselves9
Powder that does not dissolve cleanly, or a solution that is cloudy or discoloured
A label or certificate that does not match the order, or a blend certificate with a single purity figure
Community Language
Ipa, Ipam
Ipamorelin. A pentapeptide ghrelin-receptor agonist with two unnatural D-amino acids and one aminoisobutyric acid.5
CJC/Ipa
A fixed-ratio blend or co-injection of CJC-1295 without DAC and ipamorelin. No study has tested the combination, and one half of it has never been studied in humans at all.
Gly-ipamorelin
Ipamorelin with an extra N-terminal glycine, identified in black-market product by anti-doping laboratories.1 Not a product anyone is knowingly buying.
Category 2
The FDA's interim classification for nominated compounding substances that may present significant safety risks. Ipamorelin acetate remains in it under the 503B policy.3
Certificate of analysis
A laboratory report on one batch. It describes the batch tested, not necessarily the vial received.
Related ONPEPS Coverage
Ipamorelin library entry: the selectivity, the failed trials and the fat finding
Compounded, gray market and counterfeit semaglutide: what the regulators have documented
Sources
Krug O, Thomas A, Malerød-Fjeld H, Dehnes Y, Laussmann T, Feldmann I, et al. Analysis of new growth promoting black market products. Growth Horm IGF Res. 2018;41:1-6. Paywalled. pubmed.ncbi.nlm.nih.gov/29864719
Gajda PM, Holm NB, Hoej LJ, Rasmussen BS, Dalsgaard PW, Reitzel LA, et al. Glycine-modified growth hormone secretagogues identified in seized doping material. Drug Test Anal. 2019;11(2):350-354. Paywalled. pubmed.ncbi.nlm.nih.gov/30136411
US Food and Drug Administration. Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Entries for ipamorelin acetate. Content current as of 22 April 2026. fda.gov
US Food and Drug Administration. Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, December 4, 2024. Approved 21 February 2025. fda.gov
Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. Open access. pubmed.ncbi.nlm.nih.gov/9849822
US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Drug Alerts and Statements. Cited for the agency's general guidance on multi-dose vials and fabricated labels. fda.gov
US Food and Drug Administration. Warning Letter: Gram Peptides. MARCS-CMS 721806, 31 March 2026. fda.gov
Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Front Endocrinol (Lausanne). 2026;17:1822475. Open access. pubmed.ncbi.nlm.nih.gov/42395176
Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. 2001;280(1):132-138. Paywalled. pubmed.ncbi.nlm.nih.gov/11162489
Not Medical Advice
Ipamorelin holds no marketing authorisation for human use in any jurisdiction. If you are already using a product obtained outside a pharmacy, the route back to oversight is a clinician who knows what you have taken.
Regulatory sources verified 16 September 2026. The FDA's compounding categories are under active revision and the record changes frequently. Re-verify before relying on any statement here.